[go: up one dir, main page]

MXPA01002007A - Tableta bioadhesiva bucal de liberacion extendida. - Google Patents

Tableta bioadhesiva bucal de liberacion extendida.

Info

Publication number
MXPA01002007A
MXPA01002007A MXPA01002007A MXPA01002007A MXPA01002007A MX PA01002007 A MXPA01002007 A MX PA01002007A MX PA01002007 A MXPA01002007 A MX PA01002007A MX PA01002007 A MXPA01002007 A MX PA01002007A MX PA01002007 A MXPA01002007 A MX PA01002007A
Authority
MX
Mexico
Prior art keywords
active ingredient
protected
tablet
moisture
extended release
Prior art date
Application number
MXPA01002007A
Other languages
English (en)
Inventor
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22265404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA01002007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MXPA01002007A publication Critical patent/MXPA01002007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una tableta bioadhesiva en donde el ingrediente activo puede ser protegido del agua o del ambiente que lo rodea, protegiendolo de esa manera del metabolismo o de otra degradacion causada por la humedad, por las enzimas, o por los efectos del pH, y haciendolo biodisponible solamente a una velocidad controlada; el ingrediente activo puede ser protegido de la humedad durante el procedimiento de fabricacion y de forma muy importante puede ser protegido de la humedad y del medio ambiente septico inmediato hasta un momento despues que el paciente ha aplicado la tableta, y solamente a una velocidad lenta y controlada; esto ultimo se realiza mediante el procedimiento de hidratacion progresiva, en donde el ingrediente activo se mantiene protegido durante muchas horas despues de su administracion; ademas, tambien como resultado del procedimiento de hidratacion progresiva, se logra la liberacion controlada y sostenida debido solamente a que una parte del ingrediente activo que es la fraccion hidratada (acuosa) de la tableta que esta disponible para su absorcion (biodisponible).
MXPA01002007A 1998-08-25 1999-08-24 Tableta bioadhesiva bucal de liberacion extendida. MXPA01002007A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9784398P 1998-08-25 1998-08-25
US09/379,310 US6248358B1 (en) 1998-08-25 1999-08-23 Bioadhesive progressive hydration tablets and methods of making and using the same
PCT/US1999/019260 WO2000010536A1 (en) 1998-08-25 1999-08-24 Extended release buccal bioadhesive tablet

Publications (1)

Publication Number Publication Date
MXPA01002007A true MXPA01002007A (es) 2002-06-04

Family

ID=22265404

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01002007A MXPA01002007A (es) 1998-08-25 1999-08-24 Tableta bioadhesiva bucal de liberacion extendida.

Country Status (25)

Country Link
US (1) US6248358B1 (es)
EP (1) EP1105104B1 (es)
JP (2) JP5411398B2 (es)
KR (1) KR100716702B1 (es)
CN (2) CN1259903C (es)
AR (1) AR036972A1 (es)
AT (1) ATE306253T1 (es)
AU (1) AU754880B2 (es)
BR (1) BR9913239B1 (es)
CA (1) CA2341375C (es)
DE (1) DE69927694T2 (es)
DK (1) DK1105104T3 (es)
ES (1) ES2251220T3 (es)
HU (1) HU226591B1 (es)
IL (1) IL141445A (es)
MA (1) MA24964A1 (es)
MX (1) MXPA01002007A (es)
MY (2) MY125919A (es)
NO (1) NO331255B1 (es)
NZ (1) NZ509963A (es)
PE (1) PE20001036A1 (es)
RU (1) RU2227022C2 (es)
UA (1) UA78967C2 (es)
WO (1) WO2000010536A1 (es)
ZA (1) ZA995445B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
AU2005203703B2 (en) * 1998-08-25 2007-05-24 Columbia Laboratories (Bermuda) Limited Bioadhesive progressive hydration tablets
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
WO2002087552A2 (en) * 2001-05-01 2002-11-07 Mcgill University Androgen-mediated neuroprotection and uses thereof
CN101327326A (zh) * 2001-10-29 2008-12-24 哥伦比亚实验室(百慕大群岛)有限公司 阴道给药治疗骨盆痛和不孕症的抗节律障碍剂
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
PE20040134A1 (es) * 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
CN1684667A (zh) * 2002-08-02 2005-10-19 兰贝克赛实验室有限公司 贮藏稳定的福辛普利钠片剂
RU2213558C1 (ru) * 2002-09-30 2003-10-10 Нестерук Владимир Викторович Антибактериальное средство
WO2004043434A1 (en) * 2002-11-14 2004-05-27 Shear/Kershman Laboratories, Inc. Oral testosterone delivery system with improved sustained release
EA012306B1 (ru) * 2003-01-24 2009-08-28 Магле Холдинг Аб Композиционный материал для доставки через слизистые оболочки
SE0302947D0 (sv) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
PT1781260E (pt) * 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CN101330903B (zh) 2005-12-13 2015-07-08 生物递送科学国际公司 防滥用的经黏膜给药装置
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US20070248655A1 (en) * 2006-04-21 2007-10-25 Haley Jeffrey T Lenticular shaped protective mouth sore discs
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
EP1987820A1 (en) * 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
US20090269403A1 (en) * 2008-04-24 2009-10-29 Shaked Ze Ev Oral contraceptive dosage forms and methods of making such dosage forms
EP2163240A1 (en) * 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
ES2929471T3 (es) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Administración segura de desmopresina
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
ES2660116T3 (es) 2011-08-18 2018-03-20 Biodelivery Sciences International, Inc. Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
ES2961736T3 (es) 2019-04-05 2024-03-13 Gedea Biotech Ab Formulación de comprimido vaginal

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133862A (en) 1960-07-22 1964-05-19 Miles Lab Buccal tablet containing vitamin a and sodium proteinate
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5225196A (en) * 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
EP0159604B1 (en) 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
JPS60215622A (ja) * 1984-04-09 1985-10-29 Toyobo Co Ltd 口腔粘膜適用徐放性製剤
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE3776116D1 (de) 1986-12-30 1992-02-27 American Cyanamid Co Zusammensetzung die ein polycarbophil enthaelt.
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US6017521A (en) * 1989-10-31 2000-01-25 Columbia Laboratories, Inc. Use of polycarboxylic acid polymers to treat vaginal infections
EP0452334A4 (en) * 1989-10-31 1991-12-11 Watson Laboratoires, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
EP0459373A3 (en) * 1990-05-31 1993-09-08 The B.F. Goodrich Company Bioadhesive carboxylic polymer composition and method relating thereto
FR2665357B1 (fr) 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5686094A (en) 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
JP2609022B2 (ja) 1990-11-29 1997-05-14 北陸製薬株式会社 ポリカルボフィルカルシウム含有製剤
JPH06100466A (ja) 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
GR1002418B (el) * 1992-07-29 1996-08-21 Johnson & Johnson Consumer Products Inc. Βιοεπισυναπτομενες συνθεσεις θεραπειας και μεθοδοι χρησης.
FI933979A0 (fi) 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioeroderbar anordning foer dosering av aktiva ingredienser
US5458884A (en) 1992-09-10 1995-10-17 Britton; Peter Bioerodible device for administering active ingredients
US5298017A (en) 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
FR2712807B1 (fr) * 1993-11-24 1996-02-23 Vetoquinol Sa Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE69510894T2 (de) 1994-06-16 2000-02-03 Pharmacia & Upjohn S.P.A., Mailand Verfahren zur Herstellung mucoadhesiver Stärke
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
RU2095064C1 (ru) * 1995-11-24 1997-11-10 Анатолий Борисович Давыдов Средство для снижения агрегации тромбоцитов в кровеносной системе
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5807575A (en) 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds

Also Published As

Publication number Publication date
HU226591B1 (en) 2009-04-28
MY133365A (en) 2007-11-30
MY125919A (en) 2006-08-30
WO2000010536A8 (en) 2000-06-15
AU754880B2 (en) 2002-11-28
UA78967C2 (uk) 2007-05-10
US6248358B1 (en) 2001-06-19
KR100716702B1 (ko) 2007-05-14
NO20010919D0 (no) 2001-02-23
ES2251220T3 (es) 2006-04-16
JP5411398B2 (ja) 2014-02-12
IL141445A0 (en) 2002-03-10
JP2004500317A (ja) 2004-01-08
WO2000010536A1 (en) 2000-03-02
CN1323201A (zh) 2001-11-21
CA2341375A1 (en) 2000-03-02
KR20010072924A (ko) 2001-07-31
DE69927694T2 (de) 2006-08-10
NO331255B1 (no) 2011-11-07
AU5582699A (en) 2000-03-14
ZA995445B (en) 2000-11-27
EP1105104B1 (en) 2005-10-12
CN1879608A (zh) 2006-12-20
BR9913239A (pt) 2001-05-15
CN1259903C (zh) 2006-06-21
JP2010248231A (ja) 2010-11-04
PE20001036A1 (es) 2000-10-12
CA2341375C (en) 2006-07-11
ATE306253T1 (de) 2005-10-15
NO20010919L (no) 2001-03-22
NZ509963A (en) 2004-11-26
WO2000010536A9 (en) 2000-08-24
HUP0103218A2 (hu) 2001-12-28
IL141445A (en) 2005-12-18
RU2227022C2 (ru) 2004-04-20
DK1105104T3 (da) 2006-02-06
DE69927694D1 (de) 2005-11-17
HK1034895A1 (en) 2001-11-09
MA24964A1 (fr) 2000-04-01
BR9913239B1 (pt) 2010-11-16
AR036972A1 (es) 2004-10-20
EP1105104A1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
MXPA01002007A (es) Tableta bioadhesiva bucal de liberacion extendida.
MY128628A (en) Bioadhesive progressive hydration tablets
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
AUPR105400A0 (en) Processes and compositions for water treatment
MXPA02010502A (es) Un dispositivo intravaginal que contiene progesterona, util como inductor del celo en bovinos productores de carne y leche y el procedimiento para prepararlo.
HK1040198A1 (zh) 用於預防和治療內髒痛的加巴噴丁衍生物
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
HUP9903308A2 (hu) Granulátum nagy mennyiségű hatóanyagot tartalmazó, gyorsan széteső és gyorsan oldódó készítmények előállítására
MY137768A (en) Rapidly disintegrating methylcellulose tablets
WO2004108067A3 (en) Programmed drug delivery system
WO2002010137A3 (en) Indazole derivatives as JNK inhibitors
CA2301135A1 (en) Rapidly disintegrating methylcellulose tablets
AU2001272852A1 (en) Composition for the treatment of migraine
WO2000041528A3 (en) Improved controlled release compositions and method
HUP0105302A3 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation
HK1046631A1 (zh) 含有酮替芬的眼药组合物
EP1900802A3 (en) Toilet bar having a latent acidifier
AU6386801A (en) System for the release of active ingredients
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU3822900A (en) Process for the treatment of fly ash, using hydrochloric acid
HUP0103657A3 (en) Pharmaceutically active plant preparation for the treatment of migraine
AU4750200A (en) Effervescent tablets comprising tabletting auxiliary agents and method for the production thereof
WO1998052410A3 (en) A microbiocidal formulation
AU5969300A (en) Pressure treatment of cells
GB2363801A (en) Detergent compositions

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees